Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis …
V Poeschel, G Held, M Ziepert, M Witzens-Harig… - The Lancet, 2019 - thelancet.com
Background Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin …
vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin …
2-deoxy-2-[18F] FDG PET Imaging for Therapy Assessment in Hodgkin's and Non-Hodgkin Lymphomas
N Withofs, C Bonnet, R Hustinx - PET clinics, 2024 - pet.theclinics.com
The estimated new cases of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) in
the United States in 2022 are 8540 and 80,470, respectively, and the estimated deaths are …
the United States in 2022 are 8540 and 80,470, respectively, and the estimated deaths are …
The new German evidence-based guideline on diffuse large B-cell lymphoma—key aspects for radiation oncologists
M Oertel, C Berdel, G Held, K Herfarth… - Strahlentherapie und …, 2023 - Springer
Purpose Diffuse large B‑cell lymphoma (DLBCL) is an aggressive lymphoma subtype
treated successfully with immunochemotherapy. However, there are conflicting data on the …
treated successfully with immunochemotherapy. However, there are conflicting data on the …
Positron emission tomography‐adapted therapy in low‐risk diffuse large B‐cell lymphoma: results of a randomized, phase III, non‐inferiority trial
Q Shi, Y He, HM Yi, RJ Mu, XF Jiang… - Cancer …, 2023 - Wiley Online Library
Background The current standard of care for non‐bulky diffuse large B‐cell lymphoma
(DLBCL) patients with an International Prognostic Index (IPI) of 0 is four cycles of rituximab …
(DLBCL) patients with an International Prognostic Index (IPI) of 0 is four cycles of rituximab …
Limited‐stage diffuse large B‐cell lymphoma: current management and challenges
XY Zhang, GP Collins, DJ Cutter… - British Journal of …, 2021 - Wiley Online Library
Twenty‐five to thirty per cent of diffuse large B‐cell lymphoma (DLBCL) presents as limited
stage (I–II). Prognosis is generally excellent with four to six cycles of R‐CHOP alone …
stage (I–II). Prognosis is generally excellent with four to six cycles of R‐CHOP alone …
Updates in the management of early-stage diffuse large b-cell lymphoma
TM Habermann - Journal of the National Comprehensive Cancer …, 2021 - jnccn.org
Several important updates have emerged in the management of early-stage diffuse large B-
cell lymphoma. Three trials resulted in the approval of rituximab+ cyclophosphamide …
cell lymphoma. Three trials resulted in the approval of rituximab+ cyclophosphamide …
Weniger Zyklen, gleiche Effektivität?
M Hensel - InFo Hämatologie+ Onkologie, 2020 - Springer
Die Standardtherapie des diffus großzelligen B-Zell-Lymphoms (DLBCL) besteht seit Jahr
und Tag aus einer kombinierten Chemoimmuntherapie nach dem CHOP-Protokoll und dem …
und Tag aus einer kombinierten Chemoimmuntherapie nach dem CHOP-Protokoll und dem …
Chemoimmunotherapy for localised low-risk diffuse large B-cell lymphoma
JM Vose - The Lancet, 2019 - thelancet.com
Comment www. thelancet. com Vol 394 December 21/28, 2019 2209 the standard of care in
young patients with low-risk diffuse large B-cell lymphoma. A better approach might be an …
young patients with low-risk diffuse large B-cell lymphoma. A better approach might be an …
My burning issues in aggressive Non Hodgkin's Lymphoma
D Fuchs, MA Fridrik - memo-Magazine of European Medical Oncology, 2018 - Springer
Combined-modality treatment with chemo-immunotherapy and radiotherapy produces
excellent outcomes in early-stage, non-bulky diffuse large B‑cell lymphoma, and reducing …
excellent outcomes in early-stage, non-bulky diffuse large B‑cell lymphoma, and reducing …